Abstract
New macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the recommended treatment for MAC infection involved the use of at least two antibiotics, which includes a macrolide in combination with rifabutin, moxifloxacin and / or ethambutol. When used as prophylactic therapy in AIDS patients, azithromycin is more convenient (1200 mg, once a week) than clarithromycin (500 mg, twice a day). Ketolides are a semi-synthetic derivative of erythromycin A, which differs from erythromycin A by substitution of a 3- keto group for L-cladinose. Telithromycin has a carbamate group linked to an imidazolium and pyridium nucleus at C11- C12. In mice model, both telithromycin and ABT-733 were active in vivo against MAC.
Keywords: macrolides, clarithromycin, azithromycin, roxithromycin
Current Pharmaceutical Design
Title: Effects of Macrolides and Ketolides on Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): Luiz E. Bermudez and Yoshitaka Yamazaki
Affiliation:
Keywords: macrolides, clarithromycin, azithromycin, roxithromycin
Abstract: New macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the recommended treatment for MAC infection involved the use of at least two antibiotics, which includes a macrolide in combination with rifabutin, moxifloxacin and / or ethambutol. When used as prophylactic therapy in AIDS patients, azithromycin is more convenient (1200 mg, once a week) than clarithromycin (500 mg, twice a day). Ketolides are a semi-synthetic derivative of erythromycin A, which differs from erythromycin A by substitution of a 3- keto group for L-cladinose. Telithromycin has a carbamate group linked to an imidazolium and pyridium nucleus at C11- C12. In mice model, both telithromycin and ABT-733 were active in vivo against MAC.
Export Options
About this article
Cite this article as:
Bermudez E. Luiz and Yamazaki Yoshitaka, Effects of Macrolides and Ketolides on Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383241
DOI https://dx.doi.org/10.2174/1381612043383241 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Design of Glycogen Phosphorylase Inhibitors
Current Enzyme Inhibition Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation iMTBGO: An Algorithm for Integrating Metabolic Networks with Transcriptomes Based on Gene Ontology Analysis
Current Genomics Mechanism of Bioactive Transfer through Liposomal Bilayers
Current Drug Targets Biopolymer Catalysed Synthesis of 6-methyl-4-phenylcarbamoyl-1, 2, 3, 4- Tetrahydropyrimidine-2-ones and Evaluation of their Anti-bacterial and Anti-tubercular Activities
Current Bioactive Compounds Cytokines as Regulators of Atherosclerosis in Murine Models
Current Drug Targets Isoniazid Induced Convulsions at Therapeutic Dose in an Alcoholic and Smoker Patient
Current Drug Safety New Insights on the Nature of Latent Tuberculosis Infection and its Treatment
Inflammation & Allergy - Drug Targets (Discontinued) Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Dysprosium Hydroxide Nanowires Modified Electrode for Determination of Rifampicin Drug in Human Urine and Capsules by Adsorptive Square Wave Voltammetry
Current Pharmaceutical Analysis Oxidative Stress in HIV Patients Receiving Antiretroviral Therapy
Current HIV Research Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects
Current Topics in Medicinal Chemistry Synthesis of Novel Amides Based on Acridone Scaffold with Interesting Antineoplastic Activity
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Bacterial Protein Interaction Networks: Connectivity is Ruled by Gene Conservation, Essentiality and Function
Current Genomics Synthesis of 2-Hydroxynaphthyl Pyrazolines Containing Isoniazid Moiety: A Potential Antitubercular Agent
Letters in Organic Chemistry Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art
Current Neuropharmacology